[1]唐平阳.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析[J].医学信息,2018,31(10):129-130.[doi:10.3969/j.issn.1006-1959.2018.10.042]
　TANG Ping-yang.Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(10):129-130.[doi:10.3969/j.issn.1006-1959.2018.10.042]
点击复制

恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年10期
页码:
129-130
栏目:
药物与临床
出版日期:
2018-05-15

文章信息/Info

Title:
Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis
文章编号:
1006-1959（2018）10-0129-02
作者:
唐平阳
沧州市传染病医院肝病四科，河北 沧州 061001
Author(s):
TANG Ping-yang
Department of Hepatology,Subject Four,Cangzhou Infectious Disease Hospital,Cangzhou 061001,Hebei,China
关键词:
恩替卡韦; 抗病毒; 失代偿期; 乙肝肝硬化
Keywords:
Key words：Entecavir; Antiviral; Decompensation; Hepatitis B cirrhosis
分类号:
R512.62；R575.2
DOI:
10.3969/j.issn.1006-1959.2018.10.042
文献标志码:
A
摘要:
目的 探讨恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效和安全性。方法 本研究选取2015年2月~2016年7月我院收治的失代偿期乙型肝炎肝硬化初治患者120例，根据入院顺序的单双号分为观察组和对照组，每组60例。两组均给予常规治疗，在此基础上，对照组给予拉米夫定治疗，观察组给予恩替卡韦治疗，50周后，对比两组患者的Child-Pugh积分、血清病毒学HBV-DNA和PTA的数据。结果 治疗50周后，两组患者治疗指标均有所好转，观察组Child-Pugh 积分、HBV-DNA、PTA分别为（9.48±1.87）分、（2.87±0.12）log copies/ml、（0.79±0.11）%，优于对照组的（5.76±1.09）分、（4.58±0.46）log copies/ml、（0.61±0.12）%，差异均具有统计学意义（P＜0.05）。结论 恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效满意，值得临床推广应用。
Abstract:
Abstract：Objective To investigate the clinical efficacy and safety of entecavir antiviral therapy in patients with decompensated hepatitis B liver cirrhosis.Methods In this study,120 patients with decompensated hepatitis B cirrhosis who were treated in our hospital from February 2015 to July 2016 were selected and divided into an observation group and a control group according to the odd and even numbers of the admission order.60 cases in each group.Both groups received conventional treatment.On this basis,the control group received lamivudine treatment.The observation group received entecavir treatment.After 50 weeks,the Child-Pugh scores, serum virological HBV-DNA and PTA data were compared between the two groups.Results After 50 weeks of treatment,the treatment indicators of both groups improved.The Child-Pugh score,HBV-DNA,and PTA in the observation group were(9.48±1.87) points,(2.87±0.12)log copies/ml,(0.79±0.11)%,better than the control group(5.76±1.09)points,(4.58±0.46)log copies/ml,(0.61±0.12)%, the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of entecavir antiviral therapy in patients with decompensated hepatitis B cirrhosis is satisfactory and worthy of clinical application.

参考文献/References:

[1]雷子庆,张鑫.替诺福韦和恩替卡韦治疗乙型肝炎肝硬化的疗效对比[J].分子影像学杂志,2016,39(04):383-386.
[2]窦爱华,李冰,徐斌.肝硬化失代偿期患者死亡原因与抗病毒治疗的关系[J].现代中西医结合杂志,2015,24(24):2659-2661.
[3]占国清,李芳,李儒贵,等.三种抗病毒方案治疗失代偿期乙型肝炎肝硬化的疗效观察[J].湖北医药学院学报,2016,35(04):366-370.
[4]张萍.分析乙肝肝硬化失代偿期患者应用恩替卡韦抗病毒治疗的临床效果及安全性[J].世界最新医学信息文摘,2016,16(33):94,96.
[5]侯天恩,曾德辉,汪福群.拉米夫定联合阿德福韦酯治疗失去代偿期肝硬化的临床疗效[J].海峡药学,2016,28(04):216-217.
[6]郎静,赵龙凤,许翠萍.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效分析[J].中国现代医生,2015,53(14):71-73.

相似文献/References:

[1]姜海燕.恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化对患者肝功能及血清HA、Ⅳ-C、PC-Ⅲ水平的影响[J].医学信息,2022,35(09):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
　JIANG Hai-yan.Effect of Entecavir Combined with Compound Glycyrrhizin on Liver Function and Serum Levels of HA, Ⅳ-C and PC-Ⅲ in Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(10):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
[2]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Journal of Medical Information,2018,31(10):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[3]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,32(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
　MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Journal of Medical Information,2019,32(10):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
[4]李嘉丽,温 静,周 甦,等.主动随访督导乙型肝炎肝硬化长期依从抗病毒的效果[J].医学信息,2019,32(10):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
　LI Jia-li,WEN Jing,ZHOU Su,et al.Active Follow-up to Monitor the Long-term Compliance with Antiviral Effects of Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(10):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
[5]陈新华.拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析[J].医学信息,2019,32(18):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
　CHEN Xin-hua.Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis[J].Journal of Medical Information,2019,32(10):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
[6]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
　PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(10):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[7]周 煜.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响[J].医学信息,2019,32(22):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
　ZHOU Yu.Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(10):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
[8]张 娜.不同种类核苷类似物治疗慢性乙型肝炎患者的疗效及对HBsAg水平的影响[J].医学信息,2021,34(09):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]
　ZHANG Na.Efficacy of Different Kinds of Nucleoside Analogues in the Treatment of Patients with Chronic Hepatitis B and Their Influence on HBsAg Levels[J].Journal of Medical Information,2021,34(10):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]
[9]张 瑜,路青华,曹海芳,等.聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响[J].医学信息,2021,34(17):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
　ZHANG Yu,LU Qing-hua,CAO Hai-fang,et al.Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2021,34(10):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
[10]谭子跃.干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响[J].医学信息,2023,36(20):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]
　TAN Zi-yue.Effect of Interferon Combined with Entecavir in the Treatment of Patients with Hepatitis B and its Effect on Liver Function[J].Journal of Medical Information,2023,36(10):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]

更新日期/Last Update: 2018-05-15